Publication

Article

Oncology Nursing News

April 2011
Volume5
Issue 2

Myths and Facts About Kidney Cancer

March was National Kidney Month, so here is an opportunity to test your knowledge about kidney cancer.

March was National Kidney Month. Here are some myths and facts about kidney cancer.

MYTH:

1. Renal cell carcinoma is the only type of kidney cancer that can occur. The most common type of kidney cancer is renal cell carcinoma; however, less common types of kidney cancer include transitional cell carcinoma that affects the ureters but begins in the kidneys, and Wilms’ tumor of the kidney that can occur in children.

FACT:

2. People with Von Hippel-Lindau syndrome are at higher risk for developing kidney cancer. Von Hippel-Lindau (VHL) syndrome, a rare familial disease caused by an abnormal VHL gene, increases a person’s risk of developing kidney cancer. The gene can also cause cysts or tumors to develop in the eyes, brain, and other body parts. Family members of patients with VHL who have kidney cancer can be tested to determine if they have the abnormal VHL gene, and if they do, can work with their healthcare providers to detect kidney cancer and VHL-related cysts/tumors before symptoms develop.

MYTH

3. Blood in the urine is a sure sign of kidney cancer. : While blood-colored, rusty, or deep red urine is a symptom of kidney cancer, red-appearing urine may also be a sign of noncancerous disorders, such as a urinary tract infection. Red-tinged urine should never be ignored; it should be promptly evaluated by a healthcare provider. Other signs and symptoms of kidney cancer include persistent fl ank pain, lumps or masses in abdominal tissue, fatigue, fever, and weight loss.

Related Videos
Tiago Biachi, MD, PhD
Adam E. Singer, MD, PhD, Health Sciences Clinical Instructor, medicine, division lead, kidney cancer, Division of Hematology/Oncology, UCLA Health
Alberto Montero, MD, MBA, CPHQ
Thomas Westbrook, MD, assistant professor, Rush University Medical Center
Alan Tan, MD, Vanderbilt-Ingram Cancer Center
Chad Tang, MD
Martin H. Voss, MD
Martin H. Voss, MD
Alexandra Drakaki, MD, PhD
Toni Choueiri, MD, director, Lank Center for Genitourinary Oncology, co-leader, kidney cancer program, Dana-Farber Cancer Institute; Jerome and Nancy Kohlberg Chair, professor, medicine, Harvard Medical School